[Left atrial appendage occlusion in patients with nonvalvular atrial fibrillation : Present evidence, ongoing...

Area of Science:

• Cardiology
• Neurology
• Medical Devices

Background:

• Atrial fibrillation (AF) is a leading cause of ischemic stroke, with approximately 20% of strokes linked to this arrhythmia.
• Oral anticoagulation is effective for stroke prevention in AF but is contraindicated or poorly tolerated in a significant patient subset.
• Left atrial appendage occlusion (LAAA) presents an alternative stroke prevention strategy for specific AF patient groups.

Purpose of the Study:

• To review current evidence on left atrial appendage occlusion for stroke prevention in nonvalvular atrial fibrillation (NVAF).
• To identify knowledge gaps and ongoing clinical trials evaluating LAAA efficacy and safety.
• To discuss the role of LAAA in patients with contraindications or adherence issues with oral anticoagulation, and after severe bleeding events.

Main Methods:

• Review of existing scientific literature and clinical evidence regarding LAAA.
• Analysis of data from ongoing and completed clinical studies on LAAA.
• Summary of the design and objectives of the CLOSURE-AF randomized multicenter study.

Main Results:

• Current evidence does not support a general recommendation for LAAA in all NVAF patients.
• LAAA is a viable treatment option for patients experiencing severe anticoagulation-related bleeding or having contraindications to oral anticoagulation.
• Further randomized studies are crucial to confirm LAAA benefits in selected NVAF populations.

Conclusions:

• Left atrial appendage occlusion is a promising alternative for stroke prevention in specific nonvalvular atrial fibrillation patient groups.
• Clarification is needed regarding the feasibility of discontinuing antiplatelet therapy post-catheter-based LAAA due to bleeding risks.
• Ongoing research, including the CLOSURE-AF study, aims to provide definitive evidence on LAAA's role in stroke prevention.